CL2019000122A1 - Un derivado de oxazina para usar en la prevención de la enfermedad de alzheimer en pacientes de riesgo. - Google Patents
Un derivado de oxazina para usar en la prevención de la enfermedad de alzheimer en pacientes de riesgo.Info
- Publication number
- CL2019000122A1 CL2019000122A1 CL2019000122A CL2019000122A CL2019000122A1 CL 2019000122 A1 CL2019000122 A1 CL 2019000122A1 CL 2019000122 A CL2019000122 A CL 2019000122A CL 2019000122 A CL2019000122 A CL 2019000122A CL 2019000122 A1 CL2019000122 A1 CL 2019000122A1
- Authority
- CL
- Chile
- Prior art keywords
- alzheimer
- risk
- disease
- prevention
- patients
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 2
- 150000004893 oxazines Chemical class 0.000 title 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 abstract 2
- 229940125759 BACE1 protease inhibitor Drugs 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A UN INHIBIDOR DE BACE–1 DERIVADO DE OXAZINA Y COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN DICHO DERIVADO DE OXAZINA PARA USAR EN LA PREVENCIÓN DE LA ENFERMEDAD DE ALZHEIMER EN UN PACIENTE CON RIESGO DE DESARROLLAR LOS SÍNTOMAS CLÍNICOS DE LA ENFERMEDAD DE ALZHEIMER Y, EN PARTICULAR, EN DONDE EL PACIENTE CON RIESGO DE DESARROLLAR LOS SÍNTOMAS CLÍNICOS DE LA ENFERMEDAD DE ALZHEIMER ES PORTADOR DE UNA O DOS COPIAS DEL ALELO APOE4.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16180233 | 2016-07-19 | ||
| EP16193779 | 2016-10-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019000122A1 true CL2019000122A1 (es) | 2019-04-12 |
Family
ID=59626646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019000122A CL2019000122A1 (es) | 2016-07-19 | 2019-01-16 | Un derivado de oxazina para usar en la prevención de la enfermedad de alzheimer en pacientes de riesgo. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20180036315A1 (es) |
| EP (1) | EP3487504A1 (es) |
| JP (1) | JP2019524743A (es) |
| KR (1) | KR20190030691A (es) |
| CN (1) | CN109475562A (es) |
| AU (1) | AU2017298651A1 (es) |
| BR (1) | BR112019000902A2 (es) |
| CA (1) | CA3028629A1 (es) |
| CL (1) | CL2019000122A1 (es) |
| IL (1) | IL264040A (es) |
| JO (1) | JOP20190003A1 (es) |
| MA (1) | MA45719A (es) |
| MX (1) | MX2019000834A (es) |
| PH (1) | PH12018502703A1 (es) |
| RU (1) | RU2019101210A (es) |
| SG (1) | SG11201811022TA (es) |
| TW (1) | TW201805004A (es) |
| WO (1) | WO2018015868A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190081A1 (ar) | 2016-10-13 | 2019-04-11 | Novartis Ag | مشتق أوكسازين للاستخدام في علاج أو الوقاية من اعتلال وعائي دماغي نشواني |
| CN113209087B (zh) * | 2020-02-05 | 2023-11-07 | 歌礼药业（浙江）有限公司 | 一种抑制冠状病毒的药物组合物及其用途 |
| KR102321601B1 (ko) * | 2020-11-19 | 2021-11-05 | 주식회사 휴런 | 뇌 영상을 이용한 알츠하이머병의 생물학적 분류 장치 및 방법 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106117193B (zh) | 2011-01-13 | 2019-09-13 | 诺华股份有限公司 | 新的杂环衍生物及其在神经性疾病治疗中的应用 |
| EA201490774A1 (ru) * | 2011-10-13 | 2014-08-29 | Новартис Аг | Новые производные оксазина и их применение при лечении заболевания |
-
2017
- 2017-06-16 JO JOP/2019/0003A patent/JOP20190003A1/ar unknown
- 2017-07-17 TW TW106123742A patent/TW201805004A/zh unknown
- 2017-07-17 JP JP2019502566A patent/JP2019524743A/ja active Pending
- 2017-07-17 AU AU2017298651A patent/AU2017298651A1/en not_active Abandoned
- 2017-07-17 EP EP17752181.2A patent/EP3487504A1/en not_active Withdrawn
- 2017-07-17 CA CA3028629A patent/CA3028629A1/en not_active Abandoned
- 2017-07-17 RU RU2019101210A patent/RU2019101210A/ru not_active Application Discontinuation
- 2017-07-17 MA MA045719A patent/MA45719A/fr unknown
- 2017-07-17 WO PCT/IB2017/054307 patent/WO2018015868A1/en not_active Ceased
- 2017-07-17 CN CN201780043581.9A patent/CN109475562A/zh active Pending
- 2017-07-17 MX MX2019000834A patent/MX2019000834A/es unknown
- 2017-07-17 US US15/651,845 patent/US20180036315A1/en not_active Abandoned
- 2017-07-17 KR KR1020197001453A patent/KR20190030691A/ko not_active Withdrawn
- 2017-07-17 SG SG11201811022TA patent/SG11201811022TA/en unknown
- 2017-07-17 BR BR112019000902-7A patent/BR112019000902A2/pt not_active Application Discontinuation
-
2018
- 2018-12-20 PH PH12018502703A patent/PH12018502703A1/en unknown
- 2018-12-31 IL IL264040A patent/IL264040A/en unknown
-
2019
- 2019-01-16 CL CL2019000122A patent/CL2019000122A1/es unknown
-
2020
- 2020-07-17 US US16/931,783 patent/US20200345746A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201811022TA (en) | 2019-02-27 |
| IL264040A (en) | 2019-01-31 |
| EP3487504A1 (en) | 2019-05-29 |
| BR112019000902A2 (pt) | 2019-04-30 |
| MX2019000834A (es) | 2019-07-04 |
| JOP20190003A1 (ar) | 2019-01-10 |
| PH12018502703A1 (en) | 2019-11-11 |
| WO2018015868A1 (en) | 2018-01-25 |
| US20180036315A1 (en) | 2018-02-08 |
| US20200345746A1 (en) | 2020-11-05 |
| AU2017298651A1 (en) | 2018-12-20 |
| KR20190030691A (ko) | 2019-03-22 |
| CN109475562A (zh) | 2019-03-15 |
| TW201805004A (zh) | 2018-02-16 |
| CA3028629A1 (en) | 2018-01-25 |
| MA45719A (fr) | 2019-05-29 |
| JP2019524743A (ja) | 2019-09-05 |
| RU2019101210A (ru) | 2020-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR132544A2 (es) | ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
| CL2021000382A1 (es) | Compuestos novedosos de sulfonamidaurea | |
| ECSP19015192A (es) | Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos | |
| CO2019001043A2 (es) | Composición de cannabis | |
| BR112016015449A8 (pt) | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos | |
| UY36153A (es) | ?inhibidores de la fosfoinosítido 3-quinasa delta para su uso en el tratamiento de una enfermedad cutánea inmunoampollosa mediada por autoanticuerpos? | |
| BR112018073642A2 (pt) | imunomoduladores para imagiologia tep | |
| MA39995B1 (fr) | Composés destinés à traiter l'amyotrophie spinale | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
| CL2018001192A1 (es) | Análogos de saponina triterpeno | |
| BR112016028845A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| CO2019009722A2 (es) | Dendrímeros terapéuticos | |
| BR112018073843A2 (pt) | anticorpos de peptídeo beta amiloide anti-n3pglu e usos dos mesmos | |
| GT201600250A (es) | Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
| BR112017022158A2 (pt) | compostos, composições farmacêuticas e uso de um composto | |
| BR112017025998A2 (pt) | inibidor de eixo igfbp3/tmem219, composição farmacêutica para uso no tratamento e/ou prevenção de diabetes, método para identificar um indivíduo em risco de desenvolver diabetes tipo 1 e/ou tipo 2 ou para monitorar a resposta a um tratamento terapêutico em um indivíduo e kit | |
| CL2019000122A1 (es) | Un derivado de oxazina para usar en la prevención de la enfermedad de alzheimer en pacientes de riesgo. | |
| CO2018013828A2 (es) | Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato | |
| BR112017002675A2 (pt) | métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila | |
| BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| DOP2016000325A (es) | Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas | |
| CO2019007671A2 (es) | Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer | |
| CR20170426A (es) | Inhibidores de bace 1 |